Cargando…

Epilepsy in Neurodegenerative Diseases: Related Drugs and Molecular Pathways

Epilepsy is a chronic disease of the central nervous system characterized by an electrical imbalance in neurons. It is the second most prevalent neurological disease, with 50 million people affected around the world, and 30% of all epilepsies do not respond to available treatments. Currently, the ma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cano, Amanda, Fonseca, Elena, Ettcheto, Miren, Sánchez-López, Elena, de Rojas, Itziar, Alonso-Lana, Silvia, Morató, Xavier, Souto, Eliana B., Toledo, Manuel, Boada, Mercè, Marquié, Marta, Ruíz, Agustín
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8538968/ https://www.ncbi.nlm.nih.gov/pubmed/34681281 http://dx.doi.org/10.3390/ph14101057

Ejemplares similares

Exosomes-Based Nanomedicine for Neurodegenerative Diseases: Current Insights and Future Challenges
por: Cano, Amanda, et al.
Publicado: (2023)

Nanomedicine-based technologies and novel biomarkers for the diagnosis and treatment of Alzheimer’s disease: from current to future challenges
por: Cano, Amanda, et al.
Publicado: (2021)

Cognitive and Neuropsychiatric Manifestations of COVID-19 and Effects on Elderly Individuals With Dementia
por: Alonso-Lana, Silvia, et al.
Publicado: (2020)

Extracellular vesicles, the emerging mirrors of brain physiopathology
por: Cano, Amanda, et al.
Publicado: (2023)

Biodegradable nanoparticles for the treatment of epilepsy: From current advances to future challenges
por: Bonilla, Lorena, et al.
Publicado: (2021)

Correlations between the NMR Lipoprotein Profile, APOE Genotype, and Cholesterol Efflux Capacity of Fasting Plasma from Cognitively Healthy Elderly Adults
por: de Rojas, Itziar, et al.
Publicado: (2023)

Symptomatic and Disease-Modifying Therapy Pipeline for Alzheimer’s Disease: Towards a Personalized Polypharmacology Patient-Centered Approach
por: Morató, Xavier, et al.
Publicado: (2022)

Lipid Nanoparticles for the Posterior Eye Segment
por: Bonilla, Lorena, et al.
Publicado: (2021)

State-of-the-art polymeric nanoparticles as promising therapeutic tools against human bacterial infections
por: Cano, Amanda, et al.
Publicado: (2020)

Advanced Formulation Approaches for Ocular Drug Delivery: State-Of-The-Art and Recent Patents
por: Souto, Eliana B., et al.
Publicado: (2019)

Current Applications of Nanoemulsions in Cancer Therapeutics
por: Sánchez-López, Elena, et al.
Publicado: (2019)

State of the Art on Toxicological Mechanisms of Metal and Metal Oxide Nanoparticles and Strategies to Reduce Toxicological Risks
por: García-Torra, Victor, et al.
Publicado: (2021)

Plasma extracellular vesicles reveal early molecular differences in amyloid positive patients with early-onset mild cognitive impairment
por: Cano, Amanda, et al.
Publicado: (2023)

Memantine loaded PLGA PEGylated nanoparticles for Alzheimer’s disease: in vitro and in vivo characterization
por: Sánchez-López, Elena, et al.
Publicado: (2018)

Automatized FACEmemory® scoring is related to Alzheimer’s disease phenotype and biomarkers in early-onset mild cognitive impairment: the BIOFACE cohort
por: Alegret, Montserrat, et al.
Publicado: (2022)

Dexibuprofen Biodegradable Nanoparticles: One Step Closer towards a Better Ocular Interaction Study
por: Sánchez-López, Elena, et al.
Publicado: (2020)

Role of c-Jun N-Terminal Kinases (JNKs) in Epilepsy and Metabolic Cognitive Impairment
por: Busquets, Oriol, et al.
Publicado: (2019)

Cannabidiol (CBD) Alters the Functionality of Neutrophils (PMN). Implications in the Refractory Epilepsy Treatment
por: Gómez, Claudia Taborda, et al.
Publicado: (2021)

BIOFACE: A Prospective Study of Risk Factors, Cognition, and Biomarkers in a Cohort of Individuals with Early-Onset Mild Cognitive Impairment. Study Rationale and Research Protocols
por: Esteban de Antonio, Ester, et al.
Publicado: (2021)

Metformin a Potential Pharmacological Strategy in Late Onset Alzheimer’s Disease Treatment
por: Poor, Saghar Rabiei, et al.
Publicado: (2021)

Metal-Based Nanoparticles as Antimicrobial Agents: An Overview
por: Sánchez-López, Elena, et al.
Publicado: (2020)

Harnessing acoustic speech parameters to decipher amyloid status in individuals with mild cognitive impairment
por: García-Gutiérrez, Fernando, et al.
Publicado: (2023)

Dual-drug loaded nanoparticles of Epigallocatechin-3-gallate (EGCG)/Ascorbic acid enhance therapeutic efficacy of EGCG in a APPswe/PS1dE9 Alzheimer's disease mice model
por: Cano, Amanda, et al.
Publicado: (2019)

Establishing In-House Cutoffs of CSF Alzheimer’s Disease Biomarkers for the AT(N) Stratification of the Alzheimer Center Barcelona Cohort
por: Orellana, Adelina, et al.
Publicado: (2022)

Development of Peptide Targeted PLGA-PEGylated Nanoparticles Loading Licochalcone-A for Ocular Inflammation
por: Galindo, Ruth, et al.
Publicado: (2022)

Licochalcone A: A Potential Multitarget Drug for Alzheimer’s Disease Treatment
por: Olloquequi, Jordi, et al.
Publicado: (2023)

Sex, Neuropsychiatric Profiles, and Caregiver Burden in Alzheimer’s Disease Dementia: A Latent Class Analysis
por: Rosende-Roca, Maitée, et al.
Publicado: (2022)

Potential preventive disease-modifying pharmacological strategies to delay late onset Alzheimer's disease
por: Ettcheto, Miren, et al.
Publicado: (2019)

Experimental Models for Aging and their Potential for Novel Drug Discovery
por: Folch, Jaume, et al.
Publicado: (2018)

Dexibuprofen prevents neurodegeneration and cognitive decline in APPswe/PS1dE9 through multiple signaling pathways
por: Ettcheto, Miren, et al.
Publicado: (2017)

Interaction of neuropsychiatric symptoms with APOE ε4 and conversion to dementia in MCI patients in a Memory Clinic
por: Sergi, Valero, et al.
Publicado: (2020)

Author Correction: Interaction of neuropsychiatric symptoms with APOE ε4 and conversion to dementia in MCI patients in a Memory Clinic
por: Valero, Sergi, et al.
Publicado: (2021)

Dexibuprofen ameliorates peripheral and central risk factors associated with Alzheimer’s disease in metabolically stressed APPswe/PS1dE9 mice
por: Ettcheto, Miren, et al.
Publicado: (2021)

Peroxisomal Proliferator-Activated Receptor β/δ Deficiency Induces Cognitive Alterations
por: Espinosa-Jiménez, Triana, et al.
Publicado: (2022)

A novel rhein-huprine hybrid ameliorates disease-modifying properties in preclinical mice model of Alzheimer’s disease exacerbated with high fat diet
por: Espinosa-Jiménez, Triana, et al.
Publicado: (2023)

Neuropsychiatric profiles and conversion to dementia in mild cognitive impairment, a latent class analysis
por: Roberto, Natalia, et al.
Publicado: (2021)

The Involvement of Peripheral and Brain Insulin Resistance in Late Onset Alzheimer’s Dementia
por: Folch, Jaume, et al.
Publicado: (2019)

Neurodegenerative pathways as targets for acquired epilepsy therapy development
por: Casillas‐Espinosa, Pablo M., et al.
Publicado: (2020)

Clinical performance of an antibody-free assay for plasma Aβ42/Aβ40 to detect early alterations of Alzheimer’s disease in individuals with subjective cognitive decline
por: Pascual-Lucas, María, et al.
Publicado: (2023)

Metformin restores cognitive dysfunction and histopathological deficits in an animal model of sporadic Alzheimer's disease
por: Rabieipoor, Saghar, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hal8slbe0t6rtq1sgtmdj2qur0